Open AccessEfficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non-Small-Cell Lung Cancer
Author(s) -
Chung-Yi Chang,
ChungYu Chen,
ShihChieh Chang,
Yi-Chun Lai,
Yiqun Wei
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s322967
Subject(s) - medicine , gefitinib , afatinib , erlotinib , lung cancer , oncology , performance status , epidermal growth factor receptor , regimen , progression free survival , kras , tyrosine kinase inhibitor , cancer , chemotherapy , colorectal cancer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line treatments for advanced EGFR -mutated non-small-cell lung cancer (NSCLC) patients. The efficacy of EGFR-TKIs in older patients including poor Eastern Cooperative Oncology Group (ECOG) performance status (PS) is seldom investigated.